Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-0034, Japan.
Center for Brain Integration Research, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-0034, Japan.
Mol Biol Rep. 2023 Apr;50(4):3539-3546. doi: 10.1007/s11033-022-08224-0. Epub 2023 Feb 14.
The co-administration of several therapeutic oligonucleotides targeting the same transcript is a beneficial approach. It broadens the target sites for diseases associated with various mutations or splice variants. However, little is known how a combination of antisense oligonucleotides (ASOs), which is one of the major modalities of therapeutic oligonucleotides, affects the potency. In this study, we aimed to elucidate the combination-effects of ASOs and the relationship between the target sites and potency of different combinations.
We designed 113 ASOs targeting human superoxide dismutase 1 pre-mRNA and found 13 ASOs that had comparable silencing activity in vitro. An analysis of combination-effects on the silencing potency of 37 pairs of two ASOs on HeLa cells revealed that 29 pairs had comparable potency to that of two ASOs; on the other hand, eight pairs had reduced potency, indicating a negative impact on the activity. A reduced potency was seen in pairs targeting the same intron, exon-intron combination, or two different introns. The sequence distance of target sites was not the major determinant factor of combination-effects. In addition, a combination of three ASOs preserving the potency could be designed by avoiding two-ASO pairs, which had a reduced potency.
This study revealed that more than half of the combinations retain their potency by paring two ASOs; in contrast, some pairs had a reduced potency. This could not be predicted only by the distance between the target sites.
同时使用几种针对同一转录物的治疗性寡核苷酸是一种有益的方法。它拓宽了与各种突变或剪接变体相关疾病的靶标位点。然而,对于寡核苷酸(ASO)的组合如何影响效力,人们知之甚少。ASO 是治疗性寡核苷酸的主要方式之一。在这项研究中,我们旨在阐明 ASO 的组合效应以及不同组合的靶标位点和效力之间的关系。
我们设计了 113 种靶向人超氧化物歧化酶 1 前体 mRNA 的 ASO,并发现了 13 种在体外具有可比沉默活性的 ASO。对 37 对两种 ASO 对 HeLa 细胞沉默效力的组合效应进行分析,发现 29 对具有与两种 ASO 相当的效力;另一方面,有 8 对具有降低的效力,表明对活性有负面影响。针对同一内含子、内含子-外显子组合或两个不同内含子的对具有降低的效力。靶标位点的序列距离不是组合效应的主要决定因素。此外,通过避免具有降低效力的两个 ASO 对,可以设计出保持效力的三种 ASO 组合。
这项研究表明,通过配对两种 ASO,超过一半的组合保留其效力;相比之下,一些组合的效力降低。仅通过靶标位点之间的距离无法预测这一点。